Breast Cancer Clinical Trial
Official title:
Cancer Prevention and Treatment Among African American Older Adults: Screening Trial
Verified date | April 2018 |
Source | Johns Hopkins Bloomberg School of Public Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Centers for Medicare and Medicaid Services (CMS) has awarded cooperative agreements to 6
sites from across the country (Salt Lake City, UT, Molokai, HI, Houston, TX, Newark, NJ,
Detroit, MI, and Baltimore City) to participate in a national 4-year demonstration (September
15, 2006 to September 30, 2010). One goal of the demonstration is to reduce disparities in
cancer screening among seniors from U.S. racial and ethnic minority populations. Each site
will focus on a specific racial/ethnic minority group, and collaborate with CMS in project
implementation. A Core questionnaire, the Cancer Screening Assessment (CSA) will be
administered at baseline to all participants in the demonstration. Participant
identification, randomization, and intervention implementation will be standardized across
sites.
Goal: The proposal developed by the Johns Hopkins Bloomberg School of Public Health in
collaboration with the Baltimore City Community Health Coalition is designed to address
persistent disparities in screening for breast, cervix, colon/rectum and prostate cancer
among Baltimore City's seniors.
Primary Objective: Conduct a randomized controlled trial (target N = 2,874) within a project,
to compare the efficacy of 2 interventions that differ in intensity to improve continuity and
outcomes of care among African Americans seniors.
Among African American seniors, compared to a less intensive intervention (general
information and educational materials), does the addition of facilitation services delivered
by a health coordinator result in a greater improvement in adherence to cancer screening
recommendations among those who are not known to have cancer?
Study Population: We will recruit African American residents of Baltimore, age 65 years or
older, and currently enrolled in Medicare Parts A and B. (Baltimore City's 82,202 seniors
represent 13% of its population, and account for 68% of the City's cancer deaths. Among these
seniors, 96% have Medicare Parts A and B, 54.5% have income levels at less than 250% of the
federal poverty guideline, and 55.6% are African American.)
Eligible participants will respond to a baseline questionnaire, Cancer Screening Assessment
(CSA). They will then be randomized to receive a less intensive or more intensive
intervention. The less intensive group will receive general information about cancer and
Medicare covered services, and instructions to discuss the information with their primary
care doctor. The more intensive group will receive the same information as the less intensive
group receives, plus tailored facilitation services delivered by a nurse-supervised community
health worker. The primary outcome variable will be the difference between randomized groups
in adherence to screening for breast, cervix, colon/rectum and prostate cancer.
A community advisory committee will guide all aspects of the study and will include important
stake holders (both public and private sectors), representatives from the Baltimore City
Community Health Coalition, the Baltimore City Department of Health, the Maryland Department
of Health and Mental Hygiene, community leaders, consumers, health care providers
(physicians, oncologists, nurse practitioners, physician assistants, nurses, social workers,
pathologists) and academicians.
Status | Completed |
Enrollment | 2593 |
Est. completion date | December 2010 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Age 65 or older; - Residence in Baltimore; - Enrolled in Medicare Part A; - Enrolled in Medicare Part B of Title XVIII of the Social Security Act; - Provided informed consent; - Must be free from cancer or in remission for 5 years or more Exclusion Criteria: - Age less than 65; - Residence outside of Baltimore; - Enrollment in Medicare managed care (Part C); - Residence in a chronic care facility or otherwise institutionalized; - Planning to move within the next year; - Unable or unwilling to give informed consent; - Diagnosed with cancer within 5 years or less; - Diagnosed with cancer more than 5 years ago, but cancer in remission for less than 5 years |
Country | Name | City | State |
---|---|---|---|
United States | Bloomberg School of Public Health | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins Bloomberg School of Public Health | Centers for Medicare and Medicaid Services |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference between the two intervention groups in the proportion of participants who complete at least one of the recommended screenings. | Number of days from date of randomization to date of completion of participation in the study | ||
Secondary | Adherence to maintenance screening. | Number of days beyond extended window for completion of a specific screening test | ||
Secondary | Timely notification of abnormal screening results. | Number of days between detection of an abnormal screening result and participant notification about the results | ||
Secondary | Timely follow up with specialist following abnormal screening result. | From date of detection of an abnormal screening result to date of visit with specialist | ||
Secondary | Timely diagnosis following abnormal result. | From date of detection of an abnormal screening result to date of diagnosis | ||
Secondary | Timely treatment start-up. | Number of days from the date of diagnosis to date of initiation of therapy | ||
Secondary | Improved utilization of Medicare-covered preventive services. | From date of randomization to date of completion of participation in the study | ||
Secondary | Stage at diagnosis. | At the time of diagnosis |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |